A new blood test has been approved by the FDA to find viruses in the blood that may lead to leukemias and neurologic diseases. Avioq HTLV-I/II Microelisa System is the name of the testing for viruses that can be transmitted through blood transfusions, infected syringes and breast milk of an infested mother.
Avioq HTLV-I/II Microelisa System, is the only test now available that
can be used to both screen the blood supply for antibodies to Human
T-Lymphotropic Virus Type I (HTLV-I) and Human T-Lymphotropic Virus Type
II (HTLV-II), and help diagnose infection with these viruses.
"For many years, the donor screening community has been limited to one
option for HTLV testing. We are pleased to be able to address this need
by providing the Avioq HTLV-I/II assay as an alternative test," said
Chamroen Chetty, CEO of Avioq, Inc. Dr. Chetty continues, "As we
announced last year, Ortho
Clinical Diagnostics will distribute the Avioq assay into the donor
screening market, adding HTLV-I/II to their extensive menu of assays. We
are pleased to have a partner who is as committed as we are to the donor
screening community." The introduction of the Avioq® HTLV-I/II
Microelisa System fulfills Avioq's commitment to expand its Retrovirus
For more information: http://www.news-medical.net/news/20120329/FDA-approves-Avioq-HTLV-III-Microelisa-System.aspx